{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T16:46:39Z","timestamp":1787330799439,"version":"build-2736575974"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Children with cystic fibrosis (CF) pulmonary exacerbations receive IV tobramycin therapy, with dosing guided by either log-linear regression (LLR) or Bayesian forecasting (BF).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To compare clinical and performance outcomes for LLR and BF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>A quasi-experimental intervention study was conducted at a tertiary children\u2019s hospital. Electronic medical records were extracted (from January 2015 to September 2021) to establish a database consisting of pre-intervention (LLR) and post-intervention (BF) patient admissions and relevant outcomes. All consecutive patients treated with IV tobramycin for CF pulmonary exacerbations guided by either LLR or BF were eligible.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 376 hospital admissions (LLR\u200a=\u200a248, BF\u200a=\u200a128) for CF pulmonary exacerbations were included. Patient demographics were similar between cohorts. There were no significant differences found in overall hospital length of stay, rates of re-admission within 1\u2005month of discharge or change in forced expiratory volume in the first second (\u0394 FEV1) at the end of tobramycin treatment. Patients treated with LLR on average had twice the number of therapeutic drug monitoring (TDM) blood samples collected during a single hospital admission. The timeframe for blood sampling was more flexible with BF, with TDM samples collected up to 16\u2005h post-tobramycin dose compared with 10\u2005h for LLR. The tobramycin AUC0\u201324 target of \u2265100\u2005mg\/L\u00b7h was more frequently attained using BF (72%; 92\/128) compared with LLR (50%; 124\/248) (P\u200a&amp;lt;\u200a0.001). Incidence of acute kidney injury was rare in both groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>LLR and BF result in comparable clinical outcomes. However, BF can significantly reduce the number of blood collections required during each admission, improve dosing accuracy, and provide more reliable target concentration attainment in CF children.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkac324","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T09:18:41Z","timestamp":1664443121000},"page":"3358-3366","source":"Crossref","is-referenced-by-count":5,"title":["Personalized tobramycin dosing in children with cystic fibrosis: a comparative clinical evaluation of log-linear and Bayesian methods"],"prefix":"10.1093","volume":"77","author":[{"given":"Sahand","family":"Imani","sequence":"first","affiliation":[{"name":"School of Medicine, University of Notre Dame Australia , Sydney, NSW 2010 , Australia"},{"name":"The Children\u2019s Hospital at Westmead , Sydney, NSW 2145 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic A","family":"Fitzgerald","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, The Children\u2019s Hospital at Westmead , Sydney, NSW 2145 , Australia"},{"name":"Discipline of Child and Adolescent Health, Sydney Medical School, University of Sydney , Sydney, NSW 2145 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D","family":"Robinson","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, The Children\u2019s Hospital at Westmead , Sydney, NSW 2145 , Australia"},{"name":"Discipline of Child and Adolescent Health, Sydney Medical School, University of Sydney , Sydney, NSW 2145 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiran","family":"Selvadurai","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, The Children\u2019s Hospital at Westmead , Sydney, NSW 2145 , Australia"},{"name":"Discipline of Child and Adolescent Health, Sydney Medical School, University of Sydney , Sydney, NSW 2145 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9457-8262","authenticated-orcid":false,"given":"Indy","family":"Sandaradura","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Westmead Clinical School, University of Sydney , Sydney, NSW 2145 , Australia"},{"name":"Centre for Infectious Diseases and Microbiology, Westmead Hospital , Sydney, NSW 2145 , Australia"},{"name":"Department of Infectious Diseases and Microbiology, The Children\u2019s Hospital at Westmead , Sydney, NSW 2145 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9761-0072","authenticated-orcid":false,"given":"Tony","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Children\u2019s Hospital at Westmead , Sydney, NSW 2145 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"2022112816494165300_dkac324-B1","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.pcl.2016.04.001","article-title":"Background and epidemiology","volume":"63","author":"Sanders","year":"2016","journal-title":"Pediatr Clin North Am"},{"key":"2022112816494165300_dkac324-B2","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1128\/CMR.15.2.194-222.2002","article-title":"Lung infections associated with cystic fibrosis","volume":"15","author":"Lyczak","year":"2002","journal-title":"Clin Microbiol Rev"},{"key":"2022112816494165300_dkac324-B3","doi-asserted-by":"crossref","first-page":"e1005258","DOI":"10.1371\/journal.ppat.1005258","article-title":"Cystic fibrosis lung infections: polymicrobial, complex, and hard to treat","volume":"11","author":"Filkins","year":"2015","journal-title":"PLoS Pathog"},{"key":"2022112816494165300_dkac324-B4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1183\/09031936.02.00221602","article-title":"Once-daily tobramycin in the treatment of adult patients with cystic fibrosis","volume":"19","author":"Whitehead","year":"2002","journal-title":"Eur Respir J"},{"key":"2022112816494165300_dkac324-B5","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2022112816494165300_dkac324-B6","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1034\/j.1399-3003.2000.16d30.x","article-title":"Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus","volume":"16","author":"Doring","year":"2000","journal-title":"Eur Respir J"},{"key":"2022112816494165300_dkac324-B7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1258\/jrsm.2010.s11002","article-title":"Minimizing the toxicity of aminoglycosides in cystic fibrosis","volume":"103","author":"Smyth","year":"2010","journal-title":"J R Soc Med"},{"key":"2022112816494165300_dkac324-B8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.diagmicrobio.2005.02.011","article-title":"Pharmacodynamics of tobramycin in patients with cystic fibrosis","volume":"52","author":"Mouton","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2022112816494165300_dkac324-B9","doi-asserted-by":"crossref","first-page":"106381","DOI":"10.1016\/j.ijantimicag.2021.106381","article-title":"Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: a narrative review","volume":"58","author":"Castagnola","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"2022112816494165300_dkac324-B10","first-page":"120S","article-title":"Pharmacokinetics of antimicrobial drugs in cystic fibrosis: aminoglycoside antibiotics","volume":"94","author":"Horrevorts","year":"1988","journal-title":"Chest"},{"key":"2022112816494165300_dkac324-B11","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1365-2125.2007.03045.x","article-title":"Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis\u2013a population pharmacokinetic study","volume":"65","author":"Hennig","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"2022112816494165300_dkac324-B12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/jppr.1145","article-title":"Usage and monitoring of intravenous tobramycin in cystic fibrosis in Australia and the UK","volume":"46","author":"Paviour","year":"2016","journal-title":"J Pharm Pract Res"},{"key":"2022112816494165300_dkac324-B13","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00228-014-1680-3","article-title":"Therapeutic drug monitoring of once daily aminoglycoside dosing: comparison of two methods and investigation of the optimal blood sampling strategy","volume":"70","author":"Nezic","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"2022112816494165300_dkac324-B14","author":"Therapeutic Guidelines Limited","year":"2019"},{"key":"2022112816494165300_dkac324-B15","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/phar.2193","article-title":"Reappraisal of contemporary pharmacokinetic and pharmacodynamic principles for informing aminoglycoside dosing","volume":"38","author":"Bland","year":"2018","journal-title":"Pharmacotherapy"},{"key":"2022112816494165300_dkac324-B16","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2125.1995.tb05719.x","article-title":"A suggested approach to once-daily aminoglycoside dosing","volume":"39","author":"Begg","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"2022112816494165300_dkac324-B17","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s10928-014-9392-y","article-title":"Searching for an optimal AUC estimation method: a never-ending task?","volume":"41","author":"Jawie\u0144","year":"2014","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2022112816494165300_dkac324-B18","first-page":"377","volume-title":"Methods Mol Biol","author":"Gabrielsson","year":"2012"},{"key":"2022112816494165300_dkac324-B19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40262-018-0707-9","article-title":"Monitoring of tobramycin exposure: what is the best estimation method and sampling time for clinical practice?","volume":"58","author":"Gao","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2022112816494165300_dkac324-B20","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jsps.2014.11.005","article-title":"Sampling time and indications appropriateness for therapeutically monitored drugs at a teaching university hospital in Oman","volume":"23","author":"Al Za\u2019abi","year":"2015","journal-title":"Saudi Pharm J"},{"key":"2022112816494165300_dkac324-B21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2165\/00003088-199121060-00006","article-title":"Individualising gentamicin dosage regimens","volume":"21","author":"Jelliffe","year":"1991","journal-title":"Clin Pharmacokinet"},{"key":"2022112816494165300_dkac324-B22","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/imj.13412","article-title":"Individualised medicine: why we need Bayesian dosing","volume":"47","author":"Donagher","year":"2017","journal-title":"Intern Med J"},{"key":"2022112816494165300_dkac324-B23","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/cpt.2202","article-title":"From therapeutic drug monitoring to model-informed precision dosing for antibiotics","volume":"109","author":"Wicha","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2022112816494165300_dkac324-B24","doi-asserted-by":"crossref","first-page":"6698","DOI":"10.1128\/AAC.01131-16","article-title":"Bayesian estimation of tobramycin exposure in patients with cystic fibrosis","volume":"60","author":"Barras","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2022112816494165300_dkac324-B25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13012-016-0396-4","article-title":"Achieving change in primary care\u2014causes of the evidence to practice gap: systematic reviews of reviews","volume":"11","author":"Lau","year":"2016","journal-title":"Implement Sci"},{"key":"2022112816494165300_dkac324-B26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4155\/ipk-2018-0005","article-title":"Bayesian therapeutic drug monitoring software: past, present, and future","volume":"3","author":"Drennan","year":"2018","journal-title":"Int J Pharmacokinet"},{"key":"2022112816494165300_dkac324-B27","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.2215\/CJN.15611219","article-title":"AKI!Now initiative: recommendations for awareness, recognition, and management of AKI","volume":"15","author":"Liu","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022112816494165300_dkac324-B28","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40262-014-0211-9","article-title":"Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis","volume":"54","author":"Hennig","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"2022112816494165300_dkac324-B29","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jac\/dkx427","article-title":"MIC-based dose adjustment: facts and fables","volume":"73","author":"Mouton","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2022112816494165300_dkac324-B30","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/jcph.1498","article-title":"Optimizing vancomycin use through 2-point AUC-based therapeutic drug monitoring in pediatric patients","volume":"59","author":"Suchartlikitwong","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"2022112816494165300_dkac324-B31","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/ppul.20619","article-title":"Predictors of mortality in adults with cystic fibrosis","volume":"42","author":"Courtney","year":"2007","journal-title":"Pediatr Pulmonol"},{"key":"2022112816494165300_dkac324-B32","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"2022112816494165300_dkac324-B33","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00003088-200746060-00002","article-title":"A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy","volume":"46","author":"Loh","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"2022112816494165300_dkac324-B34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/FTD.0b013e31820f40f8","article-title":"Optimal sampling strategy development methodology using maximum a posteriori Bayesian estimation","volume":"33","author":"van der Meer","year":"2011","journal-title":"Ther Drug Monit"},{"key":"2022112816494165300_dkac324-B35","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0140-6736(91)92449-C","article-title":"Severity of cystic fibrosis in patients homozygous and heterozygous for \u0394F508 mutation","volume":"337","author":"Johansen","year":"1991","journal-title":"Lancet"},{"key":"2022112816494165300_dkac324-B36","doi-asserted-by":"crossref","first-page":"190112","DOI":"10.1183\/16000617.0112-2019","article-title":"Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease","volume":"29","author":"Shteinberg","year":"2020","journal-title":"Eur Respir Rev"},{"key":"2022112816494165300_dkac324-B37","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMe1712335","article-title":"CFTR modulator therapy for cystic fibrosis","volume":"377","author":"Grasemann","year":"2017","journal-title":"N Engl J Med"},{"key":"2022112816494165300_dkac324-B38","doi-asserted-by":"crossref","first-page":"548613","DOI":"10.3389\/fcimb.2021.548613","article-title":"Changes in the cystic fibrosis airway microbiome in response to CFTR modulator therapy","volume":"11","author":"Yi","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"2022112816494165300_dkac324-B39","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jcf.2016.05.014","article-title":"Physiologic endpoints for clinical studies for cystic fibrosis","volume":"15","author":"Stanojevic","year":"2016","journal-title":"J Cyst Fibros"},{"key":"2022112816494165300_dkac324-B40","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(05)17906-9","article-title":"Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis\u2014the TOPIC study: a randomised controlled trial","volume":"365","author":"Smyth","year":"2005","journal-title":"Lancet"},{"key":"2022112816494165300_dkac324-B41","first-page":"152","article-title":"Safety of extended interval tobramycin in cystic fibrosis patients less than 6 years old","volume":"23","author":"Arends","year":"2018","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2022112816494165300_dkac324-B42","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jcf.2020.08.015","article-title":"Outcomes and endpoints reported in studies of pulmonary exacerbations in people with cystic fibrosis: a systematic review","volume":"19","author":"McLeod","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2022112816494165300_dkac324-B43","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1542\/peds.2008-1055D","article-title":"Needle pain in children: contextual factors","volume":"122","author":"Walco","year":"2008","journal-title":"Pediatrics"},{"key":"2022112816494165300_dkac324-B44","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.cmi.2021.01.015","article-title":"Cost\u2013benefit analysis comparing trough, two-level AUC and Bayesian AUC dosing for vancomycin","volume":"27","author":"Lee","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2022112816494165300_dkac324-B45","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1002\/ppul.25037","article-title":"Area under the curve achievement of once daily tobramycin in children with cystic fibrosis during clinical care","volume":"55","author":"Brockmeyer","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"2022112816494165300_dkac324-B46","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/FTD.0b013e31822c78e9","article-title":"Comparing 3 methods of monitoring gentamicin concentrations in patients with febrile neutropenia","volume":"33","author":"Avent","year":"2011","journal-title":"Ther Drug Monit"},{"key":"2022112816494165300_dkac324-B47","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.cmi.2020.03.008","article-title":"How to design a study to evaluate therapeutic drug monitoring in infectious diseases?","volume":"26","author":"M\u00e4rtson","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2022112816494165300_dkac324-B48","first-page":"92","article-title":"Infection prevention and control in cystic fibrosis: one size fits all?","volume":"36","author":"Lands","year":"2020","journal-title":"Paediatr Respir Rev"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/12\/3358\/47369472\/dkac324.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/12\/3358\/47369472\/dkac324.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T16:52:54Z","timestamp":1669654374000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/12\/3358\/6730437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":48,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,9,29]]},"published-print":{"date-parts":[[2022,11,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac324","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,9,29]]}}}